Tech Company Financing Transactions
Laigo Bio Funding Round
Laigo Bio closed a $13 million Seed funding round on 12/4/2025. Investors included Curie Capital, Kurma Partners and Angelini Ventures.
Transaction Overview
Company Name
Announced On
12/4/2025
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Seed
Investors
Curie Capital (Lead Investor)
Kurma Partners (Lead Investor)
Proceeds Purpose
The company will use the proceeds to advance its SureTAC� oncology programs towards clinical development, and to accelerate discovery and development of its three SureTAC� immunology candidate therapeutic programs for selected autoimmune and immunology indications and graft rejection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Yalelaan 62, Life Sciences Incubator Rm 2.04, Utrecht Scienc
Utrecht, 3584 CM
The Netherlands
Utrecht, 3584 CM
The Netherlands
Phone
Undisclosed
Website
Email Address
Overview
Laigo Bio is at the forefront of a revolutionary era in biotechnology - one that offers new hope for eradicating disease-causing targets through protein degradation. Even targets that have long eluded traditional therapeutic approaches are now within reach. At Laigo Bio, we have devised a novel technology (SureTACs) that facilitates the precise removal of proteins located on any cell surface.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Baker
Browse more venture capital transactions:
Prev: 12/4/2025: Brevo venture capital transaction
Next: 12/4/2025: Alinia venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs